Free Trial

Ayala Pharmaceuticals (ADXS) Competitors

Ayala Pharmaceuticals logo
$0.03 0.00 (-2.01%)
As of 05/30/2025 09:35 AM Eastern

ADXS vs. BFRI, INDP, NLSP, SNGX, MTVA, ENSC, APLM, GTBP, FRTX, and ADIL

Should you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Biofrontera (BFRI), Indaptus Therapeutics (INDP), NLS Pharmaceutics (NLSP), Soligenix (SNGX), MetaVia (MTVA), Ensysce Biosciences (ENSC), Apollomics (APLM), GT Biopharma (GTBP), Fresh Tracks Therapeutics (FRTX), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical products" industry.

Ayala Pharmaceuticals vs.

Biofrontera (NASDAQ:BFRI) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Biofrontera has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 1.2% of Biofrontera shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Biofrontera currently has a consensus price target of $2.75, suggesting a potential upside of 382.46%. Given Biofrontera's stronger consensus rating and higher probable upside, equities analysts plainly believe Biofrontera is more favorable than Ayala Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biofrontera
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ayala Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Biofrontera had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Biofrontera and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Biofrontera's score of -0.03 indicating that Ayala Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Neutral
Ayala Pharmaceuticals Neutral

Biofrontera received 9 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 69.23% of users gave Biofrontera an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
BiofronteraOutperform Votes
9
69.23%
Underperform Votes
4
30.77%
Ayala PharmaceuticalsOutperform Votes
No Votes
Underperform Votes
87
100.00%

Biofrontera has higher revenue and earnings than Ayala Pharmaceuticals. Biofrontera is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$38.00M0.14-$20.13M-$2.26-0.25
Ayala Pharmaceuticals$3.24M0.45-$48.07M-$7.980.00

Ayala Pharmaceuticals has a net margin of 0.00% compared to Biofrontera's net margin of -36.31%. Ayala Pharmaceuticals' return on equity of 0.00% beat Biofrontera's return on equity.

Company Net Margins Return on Equity Return on Assets
Biofrontera-36.31% -565.73% -96.64%
Ayala Pharmaceuticals N/A N/A N/A

Summary

Biofrontera beats Ayala Pharmaceuticals on 11 of the 18 factors compared between the two stocks.

Get Ayala Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADXS vs. The Competition

MetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.46M$6.59B$5.41B$8.39B
Dividend YieldN/A2.64%5.28%4.17%
P/E Ratio0.008.6926.8519.76
Price / Sales0.45237.36405.12134.19
Price / CashN/A65.8538.2534.64
Price / Book-0.026.336.784.51
Net Income-$48.07M$143.71M$3.23B$247.95M
7 Day PerformanceN/A1.14%1.29%1.01%
1 Month PerformanceN/A-0.08%6.84%8.28%
1 Year PerformanceN/A-2.46%25.24%8.91%

Ayala Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADXS
Ayala Pharmaceuticals
N/A$0.03
-2.0%
N/A-86.3%$1.46M$3.24M0.0020Gap Down
BFRI
Biofrontera
2.1986 of 5 stars
$0.67
+3.1%
$2.75
+310.5%
-43.6%$6.33M$37.32M-0.3070Short Interest ↑
Gap Up
INDP
Indaptus Therapeutics
3.6044 of 5 stars
$0.39
-13.1%
$8.50
+2,079.5%
-86.4%$6.25MN/A-0.236News Coverage
Positive News
Short Interest ↓
Gap Down
NLSP
NLS Pharmaceutics
N/A$1.71
+5.8%
N/A+1,301.9%$6.15MN/A0.006Positive News
Short Interest ↓
SNGX
Soligenix
1.0683 of 5 stars
$1.88
+1.1%
N/A-66.2%$6.14M$-117,029.00-0.2520Gap Up
MTVA
MetaVia
2.3545 of 5 stars
$0.70
+2.1%
$7.50
+973.0%
N/A$6.05MN/A0.008Positive News
Gap Down
ENSC
Ensysce Biosciences
0.1136 of 5 stars
$2.55
+9.0%
N/A-75.0%$6.05M$2.23M-0.0910Analyst Upgrade
Short Interest ↑
Gap Up
APLM
Apollomics
0.373 of 5 stars
$5.40
+10.4%
N/A-79.4%$5.96M$1.22M0.0045Short Interest ↑
GTBP
GT Biopharma
3.574 of 5 stars
$2.24
+0.4%
$11.00
+391.1%
-33.4%$5.68MN/A-0.398Gap Up
FRTX
Fresh Tracks Therapeutics
N/A$0.94
-0.5%
N/A+1.6%$5.59M$10.06M-0.6620
ADIL
Adial Pharmaceuticals
2.7918 of 5 stars
$0.70
+6.4%
$8.00
+1,042.9%
-54.5%$5.53MN/A-0.4820Short Interest ↑

Related Companies and Tools


This page (NASDAQ:ADXS) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners